Dementia   

And if so, how would you advise on choice of agent/dosing considerations?

How do you counsel patients on this off-label use?

Was the change that was noted in the trial clinically meaningful?Study reference: Baker et al., PMID 40720610

Especially in the era of novel AD biomarkers (blood-based, CSF, PET scans), AD treatments, and new definitions of Alzheimer's (Alz Association 2025) -...

How can treatments be combined or escalated?

From a geriatrics harm-reduction standpoint, can we recommend any particulars regarding dosing or selection of therapies when used as a last resort?

Considering poor outcomes/lack of long-term benefit for NGT/PEG placement in this population.

E.g., amyloid PET, CSF amyloid, blood-based amyloid.

What factors might drive decisions for different SSRIs and/or doses?

E.g., primary progressive aphasia

As studied in Tang H, Donahoo WT, DeKosky ST, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related De...